Aaron Seth Rosenberg, M.D., M.S. for UC Davis Health

Aaron Seth Rosenberg, M.D., M.S.

Associate Professor

To see if Aaron Seth Rosenberg is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).



Bone Marrow Transplant



Internal Medicine

Locations and Contact

UC Davis Comprehensive Cancer Center

UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817

Get Directions

Phone: 916-734-5959

Additional Numbers

Clinic Fax


Clinic Referral Phone


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Rosenberg believes in high quality, innovative, and compassionate care of his patients. Dr. Rosenberg believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.

Clinical Interests

Dr. Rosenberg's clinical interests include the diagnosis and care of multiple myeloma, and lymphoid malignancies, as well as the management of thrombosis. He is a member of the adult hematopoietic stem cell transplant team.

Research/Academic Interests

Dr. Rosenberg focuses on outcomes research related to hematologic malignancies and thrombosis, as well as developing clinical trials for patients with hematologic malignancies.


Hematology and Oncology
Malignant Hematology/Cellular Therapy and Transplantation

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.A., Wesleyan University, Middletown CT 2001

Medical School

M.D., Mount Sinai School of Medicine, New York NY 2006

Other School

M.S., Sackler School of Graduate Biomedical Sciences, Tufts University, Boston MA 2014


Internal Medicine, Temple University Hospital, Philadelphia PA 2006-2009


Internal Medicine, Temple University Hospital, Philadelphia PA 2006-2009


Internal Medicine, UC San Francisco, San Francisco CA 2013-2015


Hematology/Oncology, Tufts Medical Center, Boston MA 2010-2013


Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 Jan;63(1):231-234. doi:10.1080/10428194.2021.1975190. Epub 2021 Sep 6. PMID:34486920.

Whitney RL, White AEC, Rosenberg AS, Kravitz RL, Kim KK. Trust and shared decision-making among individuals with multiple myeloma: A qualitative study. Cancer Med. 2021 Nov;10(22):8040-8057. doi:10.1002/cam4.4322. Epub 2021 Oct 5. PMID:34608770.

Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E. Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clin Cancer Res. 2021 Sep 1;27(17):4726-4736. doi:10.1158/1078-0432.CCR-20-4622. Epub 2021 Jun 4. PMID:34088724.

Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e611-e618. doi:10.1016/j.clml.2021.02.007. Epub 2021 Mar 2. PMID:33811007.

Rosenberg AS, Facon T, Parikh K, Chung W, Srinivasan S, Kotey S, Tuscano J. Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):345-354.e4. doi:10.1016/j.clml.2020.12.021. Epub 2020 Dec 27. PMID:33563582.

Jonas BA, Fisch SC, Rosenberg AS, Hoeg RT, Tuscano JM, Abedi M. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2021 Apr 1;96(4):E114-E117. doi:10.1002/ajh.26105. Epub 2021 Feb 26. PMID:33476436.

Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. Front Oncol. 2021 Mar 11;11:649209. doi:10.3389/fonc.2021.649209. PMID:33777810.

Rosenberg AS, Brunson A, Tuscano J, Jonas BA, Fun T, Keegan THM. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J. 2021 Jan 7;11(5). doi:10.1038/s41408-020-00400-4.

Hoeg RT, Davis J, Jonas BA, Tuscano J, Rosenberg A, Abedi M. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):453-458. doi:10.1016/j.clml.2020.02.006. Epub 2020 Feb 20. PMID:32171691.